| PACB Stock May Rise Following the Deal With Chulalongkorn University |
PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand. |
zacks.com |
2025-05-12 18:05:35 |
Czytaj oryginał (ang.) |
| PacBio Board Independent Investigation Concludes Allegations Unsubstantiated |
MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the “Special Committee”) has concluded its independent investigation into previously disclosed allegations from an attorney representing an employee impacted by our recent reduction in force regarding certain employment practices and cybersecurity matters of the Company. The allegations did not involve the current, or any previously reported, financial results, and the investigation found no improper employment practices and no material inaccuracies or omissions with respect to the cybersecurity disclosures in the Company's 2024 Form 10-K. |
globenewswire.com |
2025-05-12 14:56:00 |
Czytaj oryginał (ang.) |
| PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates |
Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system shipments. |
zacks.com |
2025-05-09 17:01:03 |
Czytaj oryginał (ang.) |
| Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-09 02:00:33 |
Czytaj oryginał (ang.) |
| Pacific Biosciences of California, Inc. (PACB) Q1 2025 Earnings Call Transcript |
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance & Investor Relations Christian Henry - President & Chief Executive Officer Jim Gibson - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research David Westenberg - Piper Sandler William Ruby - TD Cowen Operator Good afternoon, everyone. And welcome to the PacBio First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-08 23:08:11 |
Czytaj oryginał (ang.) |
| Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates |
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago. |
zacks.com |
2025-05-08 22:31:13 |
Czytaj oryginał (ang.) |
| PacBio Announces First Quarter 2025 Financial Results |
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. |
globenewswire.com |
2025-05-08 20:15:00 |
Czytaj oryginał (ang.) |
| First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand |
Collaboration leverages HiFi's unique ability to reveal hidden variants, bringing a new level of precision to early life genetic screening Collaboration leverages HiFi's unique ability to reveal hidden variants, bringing a new level of precision to early life genetic screening |
globenewswire.com |
2025-05-05 13:05:00 |
Czytaj oryginał (ang.) |
| Pacific Biosciences of California (PACB) Stock Falls Amid Market Uptick: What Investors Need to Know |
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.11, marking a -1.77% move from the previous day. |
zacks.com |
2025-04-29 23:20:53 |
Czytaj oryginał (ang.) |
| PacBio Announces Plans to Improve Methylation Detection in HiFi Chemistry |
Company licenses novel deep learning-based epigenetic models from CUHK enabling the detection of 5hmC, 5mC hemimethylation, and 6mA in standard sequencing runs Company licenses novel deep learning-based epigenetic models from CUHK enabling the detection of 5hmC, 5mC hemimethylation, and 6mA in standard sequencing runs |
globenewswire.com |
2025-04-28 13:05:00 |
Czytaj oryginał (ang.) |
| Pacific Biosciences of California (PACB) Flat As Market Gains: What You Should Know |
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.17, marking no change from the previous day. |
zacks.com |
2025-04-23 23:21:08 |
Czytaj oryginał (ang.) |
| Davos Alzheimer's Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer's Disease Research in North Africa |
International research team aims to develop better understanding of Alzheimer's disease and dementia in diverse populations International research team aims to develop better understanding of Alzheimer's disease and dementia in diverse populations |
globenewswire.com |
2025-04-22 13:05:00 |
Czytaj oryginał (ang.) |
| PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million |
Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025. |
globenewswire.com |
2025-04-09 13:05:00 |
Czytaj oryginał (ang.) |
| PacBio Grants Equity Incentive Award to New Employee |
MENLO PARK, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the “Option”) covering 342,432 shares of PacBio common stock to the Company's recently hired Chief Financial Officer, Jim Gibson, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”), effective on March 31, 2025. The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4). |
globenewswire.com |
2025-04-04 23:45:00 |
Czytaj oryginał (ang.) |
| Pacific Biosciences Names Jim Gibson Chief Financial Officer |
Pacific Biosciences of California has hired Jim Gibson as its new chief financial officer, effective March 31. |
marketwatch.com |
2025-03-27 11:22:00 |
Czytaj oryginał (ang.) |
| Jim Gibson to join PacBio as Chief Financial Officer |
MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company's new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley's most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations. |
globenewswire.com |
2025-03-27 11:05:00 |
Czytaj oryginał (ang.) |
| Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors |
Pacific Biosciences of California (PACB) reachead $1.26 at the closing of the latest trading day, reflecting a +0.8% change compared to its last close. |
zacks.com |
2025-03-20 21:20:30 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain PacBio Stock in Your Portfolio Now |
PACB continues to deliver growth from its unique technologies amid macroeconomic concerns. |
zacks.com |
2025-03-20 16:06:04 |
Czytaj oryginał (ang.) |
| Scientists Solve One of Genomics' Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes |
MENLO PARK, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly published study in Nature Communications unveiling a powerful new method for analyzing some of the most complex regions of the human genome. Led by researchers from PacBio, GeneDx, and a global consortium of genomics experts, the study utilizes Paraphase, an informatics tool that, when paired with HiFi long-read sequencing, allows for high-precision variant detection and copy number analysis in 316 previously inaccessible segmental duplication regions, including 9 challenging medically-relevant genes. |
globenewswire.com |
2025-03-17 11:05:00 |
Czytaj oryginał (ang.) |
| Pacific Biosciences of California (PACB) Increases Yet Falls Behind Market: What Investors Need to Know |
In the closing of the recent trading day, Pacific Biosciences of California (PACB) stood at $1.22, denoting a +1.67% change from the preceding trading day. |
zacks.com |
2025-03-14 21:15:22 |
Czytaj oryginał (ang.) |
| Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock |
Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock |
seekingalpha.com |
2025-02-26 00:26:06 |
Czytaj oryginał (ang.) |
| PacBio to Participate in TD Cowen's 45th Annual Health Care Conference |
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 PM ET (12:10 PM PT) in Boston, MA. |
globenewswire.com |
2025-02-19 18:05:00 |
Czytaj oryginał (ang.) |
| PacBio Grants Equity Incentive Award to New Employee |
MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the “Option”) covering 400,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 300,000 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”), effective on February 10, 2025. The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4). |
globenewswire.com |
2025-02-15 01:09:00 |
Czytaj oryginał (ang.) |
| PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall |
Despite strong Service and other revenues, PacBio reports soft fourth-quarter 2024 results partly due to lower Revio system shipments. |
zacks.com |
2025-02-14 14:05:15 |
Czytaj oryginał (ang.) |
| Pacific Biosciences of California, Inc. (PACB) Q4 2024 Earnings Call Transcript |
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance and Investor Relations Christian Henry - President and CEO Michele Farmer - Chief Accounting Officer Conference Call Participants Tycho Peterson - Jefferies Kyle Mikson - Canaccord Dan Brennan - TD Cowen Doug Schenkel - Wolfe Research Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Subbu Nambi - Guggenheim Sung Ji Nam - Scotia Bank Mason Carrico - Stephens Operator Good day. And welcome to the PacBio Fourth Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2025-02-13 23:09:07 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Pacific Biosciences (PACB) Q4 Earnings: A Look at Key Metrics |
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-02-13 21:01:29 |
Czytaj oryginał (ang.) |
| Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates |
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.27 per share a year ago. |
zacks.com |
2025-02-13 20:21:14 |
Czytaj oryginał (ang.) |
| Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why |
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.44, representing a -1.37% change from its previous close. |
zacks.com |
2025-02-04 21:20:33 |
Czytaj oryginał (ang.) |
| PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service |
MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company's new Global Head of Sales & Service. |
globenewswire.com |
2025-02-03 11:05:00 |
Czytaj oryginał (ang.) |
| PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025 |
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thursday, February 13, 2025, at 4:30 pm Eastern Time. |
globenewswire.com |
2025-01-30 18:05:00 |
Czytaj oryginał (ang.) |
| PacBio Announces Appointment of Chris Smith to Board of Directors |
PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down. PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down. |
globenewswire.com |
2025-01-30 11:05:00 |
Czytaj oryginał (ang.) |
| PacBio Technology Powers Landmark Multiomic Study Published in Nature Genetics |
New sequencing approach resolves the genetic complexity of a rare Mendelian condition New sequencing approach resolves the genetic complexity of a rare Mendelian condition |
globenewswire.com |
2025-01-29 11:05:00 |
Czytaj oryginał (ang.) |
| PacBio Names Global Institute for Food Security as Canada's First Revio Certified Service Provider |
MENLO PARK, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the Global Institute for Food Security (GIFS) at the University of Saskatchewan (USask) as the first Revio PacBio Certified Service Provider (CSP) in Canada. |
globenewswire.com |
2025-01-23 11:05:00 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain PacBio Stock in Your Portfolio for Now |
PACB continues to deliver growth from its unique technologies amid business seasonality concerns. |
zacks.com |
2025-01-22 14:30:50 |
Czytaj oryginał (ang.) |
| These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar |
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. |
zacks.com |
2025-01-21 11:56:09 |
Czytaj oryginał (ang.) |
| PACB Stock Declines Despite Promising HiFi Sequencing Findings |
PacBio announces positive study results for HiFi long-read sequencing technology in identifying genetic causes of rare diseases. |
zacks.com |
2025-01-15 15:21:13 |
Czytaj oryginał (ang.) |
| PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped |
PacBio reports dismal preliminary fourth-quarter 2024 results, caused by lower instrument. New launches and clinical focus set the stage for market growth in 2025. |
zacks.com |
2025-01-15 12:01:39 |
Czytaj oryginał (ang.) |
| PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics |
MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human Genetics. The study demonstrates the impact of PacBio's HiFi long-read sequencing technology in identifying genetic causes of rare diseases, illustrating the feasibility of potentially replacing multiple diagnostic tests with a single, more comprehensive approach. |
globenewswire.com |
2025-01-14 11:05:00 |
Czytaj oryginał (ang.) |
| PacBio Announces Preliminary Fourth Quarter and Full Year Revenue |
Commenced shipment of the Vega ™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers |
globenewswire.com |
2025-01-14 11:00:00 |
Czytaj oryginał (ang.) |
| PacBio Stock May Gain Following the Collaborated Launch of GutID |
PACB and Intus Bio collaborate to launch GutID, the first commercial human gut health test. |
zacks.com |
2025-01-13 14:26:12 |
Czytaj oryginał (ang.) |
| PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference |
MENLO PARK, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, California. |
globenewswire.com |
2025-01-02 18:05:00 |
Czytaj oryginał (ang.) |
| Reasons to Retain PacBio Stock in Your Portfolio for Now |
PACB continues to deliver growth from its unique technologies amid business seasonality concerns. |
zacks.com |
2024-12-12 15:26:08 |
Czytaj oryginał (ang.) |
| Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight |
Ark Invest CEO Cathie Wood is doubling down on genomics. |
benzinga.com |
2024-12-05 10:54:34 |
Czytaj oryginał (ang.) |
| Pacific Biosciences' Cost Cuts Won't Offset Rising Competition |
Pacific Biosciences of California stock surged 50% since August despite a 24% YoY revenue decline and deteriorating gross margins due to increased costs and pricing pressures. Q3 revenue of $40 million missed analyst estimates, with SG&A expenses surpassing total revenue and gross profit margins remaining low at 28%. Pacific Biosciences has made significant cuts in R&D, which may harm long-term growth given the rapid technological advancements in the genomic market. |
seekingalpha.com |
2024-11-12 17:38:42 |
Czytaj oryginał (ang.) |
| Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought |
The rock star money manager is starting to roll with the rallying market. |
fool.com |
2024-11-12 13:55:00 |
Czytaj oryginał (ang.) |
| PacBio price target lowered to $6 from $7 at Scotiabank |
Scotiabank lowered the firm's price target on PacBio to $6 from $7 and keeps an Outperform rating on the shares. The firm lowered its FY24 and FY25 revenue estimates following the company's Q3 update, the analyst tells investors. The firm's longer-term outlook for the company, however, remains intact, believing the company is highly differentiated and the recently accelerated pace of product innovations place the company in a good position for outsized growth. |
https://thefly.com |
2024-11-11 10:56:26 |
Czytaj oryginał (ang.) |
| PacBio to Present at Upcoming Investor Conferences |
MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: |
globenewswire.com |
2024-11-08 18:05:00 |
Czytaj oryginał (ang.) |
| PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y |
PacBio Q3 2024 revenues decline year over year. However, Consumable, and Service and other revenues increase. |
zacks.com |
2024-11-08 13:10:30 |
Czytaj oryginał (ang.) |
| Pacific Biosciences of California, Inc. (PACB) Q3 2024 Earnings Call Transcript |
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Todd Friedman - Senior Director of Investor Relations Christian Henry - President and Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Kyle Nixon - Canaccord Mason Carrico - Stephens Dan Brennan - TD Cowen Jack Meehan - Nephron Research Subbu Nambi - Guggenheim Securities Madeline Mollman - Wolfe Research Operator Good day and welcome to the PacBio Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. |
seekingalpha.com |
2024-11-07 23:04:53 |
Czytaj oryginał (ang.) |
| Pacific Biosciences (PACB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates |
The headline numbers for Pacific Biosciences (PACB) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-07 22:31:24 |
Czytaj oryginał (ang.) |
| Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates |
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.27 per share a year ago. |
zacks.com |
2024-11-07 21:15:35 |
Czytaj oryginał (ang.) |
| PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028 |
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's remaining outstanding 1.50% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which PacBio will (i) issue $200 million principal amount of its 1.50% Convertible Senior Notes due 2029 (the “New Notes”), (ii) issue 20,451,570 shares (the “Shares”) of PacBio's common stock (“common stock”), and (iii) make a cash payment in the amount of $50 million (the “Cash Consideration”) in exchange for $459 million principal amount of the 2028 Notes (the “Exchange Transaction”), in a transaction exempt from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The Exchange Transaction is expected to close on or about November 21, 2024, subject to customary closing conditions. |
globenewswire.com |
2024-11-07 18:03:00 |
Czytaj oryginał (ang.) |
| PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop |
Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory |
globenewswire.com |
2024-11-07 00:35:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Encourages Investors With Losses To Join An Inquiry Into Pacific Biosciences of California Inc For Fraud |
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-11-04 13:00:00 |
Czytaj oryginał (ang.) |
| Pacific Biosciences of California, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-11-03 13:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Encourages Investors To Join An Inquiry Into Pacific Biosciences of California Inc For Securities Fraud |
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-11-02 13:00:00 |
Czytaj oryginał (ang.) |
| Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors |
Pacific Biosciences of California (PACB) reachead $2.17 at the closing of the latest trading day, reflecting a +0.46% change compared to its last close. |
zacks.com |
2024-10-31 21:16:13 |
Czytaj oryginał (ang.) |
| Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep |
BOSTON , Oct. 30, 2024 /PRNewswire/ -- Volta Labs™, a genomics applications company, announced today that it has joined the PacBio Compatible program, further expanding the partnership between Volta Labs and PacBio. Volta Labs is partnering with PacBio to offer walk-away automation for PacBio library prep, enabling labs to scale sample prep for sequencing. |
prnewswire.com |
2024-10-30 12:13:00 |
Czytaj oryginał (ang.) |
| PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500 |
New long-read sequencing chemistry reduces DNA input requirements four-fold, enables a 33% increase in data output per SMRT Cell, improves methylation calling, and expands support for multiomics New long-read sequencing chemistry reduces DNA input requirements four-fold, enables a 33% increase in data output per SMRT Cell, improves methylation calling, and expands support for multiomics |
globenewswire.com |
2024-10-29 11:05:00 |
Czytaj oryginał (ang.) |
| Pacific Biosciences of California, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-10-27 13:00:00 |
Czytaj oryginał (ang.) |